Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026
Lantheus Holdings (NASDAQ: LNTH) reported Q2 CY2026 revenue of $388.2 million, up 2.7% year on year, ahead of Wall Street expectations. Non-GAAP adjusted EPS was $1.55, 18.9% above consensus. The article also cites adjusted operating margin of 31% and analyst expectations for revenue to decline 3.2% and full-year EPS to fall from $5.95 to $5.55.
How this was made
The 30-second read
Why it matters
The article’s actionable items are the reported Q2 CY2026 revenue and adjusted EPS versus consensus, plus the stated sell-side expectations for revenue and EPS over the next 12 months.
Market read
Traders can reassess near-term positioning after the earnings beat, while also pricing in the cited forward deceleration in revenue and EPS.
What to watch
Adjusted operating margin fell to 31% (down 9.4 pp YoY), which could signal cost pressure that offsets the revenue beat.
Background
Lantheus is a radiopharmaceutical and imaging-agent company using a “Find, Fight and Follow” disease-management approach.
Ticker impact
Lantheus reported Q2 CY2026 revenue of $388.2M (+2.7% YoY) and adjusted EPS of $1.55, both above consensus.
Likely near-term support from the earnings beat, with upside capped by the guided/expected deceleration in revenue and full-year EPS.
The text provides concrete Q2 results versus expectations and also cites sell-side expectations for revenue (-3.2% next 12 months) and EPS (-6.6% full-year).
Market effects
Radiopharmaceutical peers may see read-across interest if demand trends and margin stability are interpreted as sector-relevant.
Primarily US healthcare/radiopharma sentiment; limited direct regional spillover described.
No explicit global supply, regulatory, or competitive developments beyond company-specific results.
Counterpoint
Despite the beat, the article emphasizes slowing growth (2.7% YoY) and expected declines, suggesting the market may fade the initial optimism.
Key entities
- companyLantheus Holdings
NASDAQ-listed radiopharmaceutical company reporting Q2 CY2026 results.